GlassScriptPhysician profile
Earl B Barron
NPI 1356422059
$1,099.05
in general payments reported to CMS, 2019-2025
17 companies · $24.58 in 2025
The $24.58 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $441 · 2021: $183 · 2022: $24.90 · 2023: $59.00 · 2025: $24.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $83.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $83.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $186.05 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.27 | 2019-2021 | |
| Amarin Pharma, INC. | $147.19 | 2019-2020 | |
| Abbott Laboratories | $131.88 | 2020-2025 | Aveir, Jot Dx |
| Pfizer INC. | $82.71 | 2019-2020 | |
| Novo Nordisk INC | $71.21 | 2019 | |
| Novartis Pharmaceuticals Corporation | $61.50 | 2020-2021 | |
| Amgen INC. | $45.76 | 2020 | |
| Sanofi-Aventis U.S. LLC | $35.58 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $33.73 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $33.18 | 2019-2020 | |
| Astellas Pharma US INC | $26.32 | 2020 | |
| Merck Sharp & Dohme LLC | $26.04 | 2019 | |
| Angiodynamics, INC. | $24.07 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.65 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $13.22 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Earl Barron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.